EP0000336A1 - N-benzylpyrimidinyl-amidines, procédé pour leur préparation et médicaments les contenant - Google Patents
N-benzylpyrimidinyl-amidines, procédé pour leur préparation et médicaments les contenant Download PDFInfo
- Publication number
- EP0000336A1 EP0000336A1 EP78100184A EP78100184A EP0000336A1 EP 0000336 A1 EP0000336 A1 EP 0000336A1 EP 78100184 A EP78100184 A EP 78100184A EP 78100184 A EP78100184 A EP 78100184A EP 0000336 A1 EP0000336 A1 EP 0000336A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrimidin
- trimethoxybenzyl
- amino
- acetamidine
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 NC1=*C*CN1 Chemical compound NC1=*C*CN1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
Definitions
- the invention relates to new amidino-benzylpyrimidines of the general formula I.
- R 1 , R 2 and R 3 which may be the same or different from one another, are hydrogen, methyl, methoxy or chlorine
- R 4 is alkyl having 1-6 C atoms or benzyl and R 5 and R 6 are the same or can be different from each other, hydrogen, lower alkyl with 1-4 C atoms, optionally substituted benzyl or phenyl, cyclohexyl, adamantyl or furfuryl or one of the radicals R 5 or R 6 the group -C 6 H 4 -SO 2 -NH -R 7 means, where R 7 represents the rest or a heterocyclic ring having 1 to 3 heteroatoms, which may be the same or different from one another and are nitrogen or oxygen, and which means Chlorine, methyl or methoxy can be substituted and consists of 5-6 ring members, or R 5 and R 6 together with the nitrogen to which they are connected form
- Suitable acids for the formation of pharmacologically acceptable salts are hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, lactic acid, citric acid and salicylic acid.
- the substituents R 1 , R2 and R 3 are preferably in the 3-, 4- and 5-position of the benzene ring.
- R 4 is a lower alkyl radical having 1-4 C atoms or the benzyl radical
- R 5 and R 6 which may be the same or different, are hydrogen, lower alkyl having 1-4 C atoms, benzyl, phenyl or, together with the nitrogen atom to which they are connected, are a polymethylene chain with 4 or 5 methylene groups which can be interrupted by an oxygen atom or the group> NY, where Y is methyl, benzyl or phenyl stands, or R 5 is hydrogen and R 6 is the group -C 6 H 4 -S0 2 NH-R 7 , where R 7 or the pyrimidin-2-yl-, 4-methyl-pyrimidin-2-yl-, 5-methyl-pyrimidin-2-yl-, 5-isopropyl-pyrimidin-2-yl-, 5-methoxy-pyrimidin- 2-yl, 6-methoxy-pyridazin-3-yl,
- R 1 , R 2 and R 3 are hydrogen, methyl or methoxy are further preferred, and of these particularly preferred are those in which R 1 , R 2 and R 3 are in the positions 3, 4 and 5 of the benzyl radical and are methoxy groups.
- the compounds of the formula I have an antimicrobial activity in diseases caused by bacteria and protozoa and, combined with sulfonamides, potentiate their antibacterial action. They can therefore be used, for example, for bacterial diseases of the respiratory organs, digestive organs and urinary tract as well as for throat, nose and ear infections and in general for systemic infectious diseases and malaria.
- the compounds of formula I and their salts can be combined with the sulfonamides mentioned by way of example in various mixing ratios, the ratio of compound formula I to sulfonamide being able to vary from 1:10 to 5: 1. However, preferred mixing ratios are 1: 1 to 1 : 5. As a rule, 20 to 550 mg of an active ingredient of the formula I are suitable as doses.
- the compounds of the formula I according to the invention are prepared by the methods customary for the preparation of amidines, as described, inter alia, in Houben-Weyl "Methods of Organic Chemistry", Volume 11/2, by an imidate of the general formula II wherein R 1 , R 2 , R3 and R 4 have the meaning given above and R 8 is lower alkyl having 1-4 C atoms or benzyl, with an amine of the general formula III in which R 5 and R 6 have the meaning given above, converted to the amidine of the general formula I. and then optionally converting the compound obtained into a pharmacologically acceptable acid addition salt with an acid customary for this.
- Amines of the formula III can be, for example:
- Ammonia methylamine, dimethylamine, diethylamine, benzylamine, 3,4,5-trimethoxybenzylamine, N-phenylpiperazine, furfurylamine, cyclohexylamine, pyrrolidine, piperidine, morpholine, aniline and sulfonamides such as 2-sulfanilamino-pyrimidine, 2-sulfanilamido-4 -pyrimidine, 2-sulfanilamido-5-methyl-pyrimidine, 2-sulfanilamido-5-isopropyl-pyrimidine, 2-sulfanilamido - 5-methoxy-pyrimidine, 3-sulfanilamido-6-methoxy-pyridazine, 2-sulfanilamido -3-methoxy-pyrazine, 3-sulfanilamido-5-methyl-isoxazole and 2-sulfanilamido-pyridine.
- 2-sulfanilamino-pyrimidine 2-
- These compounds can be prepared with or without a solvent.
- suitable solvents are pyridine, ethanol or water or mixtures of these solvents.
- the reaction temperatures are between 0 and 150 ° C, preferably between 20 and 120 ° C or at temperatures up to the boiling point of the solvent used.
- mice groups of 30 female mice each were infected with a lethal dose of Streptococcus agalactiae 7941 and treated 2 hours after the infection with a mixture of 300 mg of 2-sulfanilamido-4,5-dimethyloxazole + 60 mg of one of the substances according to the invention.
- a second group was treated with the mixture of 300 mg of 2-sulfanilamido-4,5-dimethyloxazole + 60 mg of trimethoprim, which served as reference substance. After 44 hours, the number of surviving animals was determined and this number was divided by the number of survivors from the group treated with the reference substance.
- trimethoprim The numerical value obtained in this way (trimethoprim factor) is a measure of the action of the substances according to the invention in comparison with trimethoprim.
- F 2 means that the substance is twice as effective as trimethoprim.
- the following table shows that the substances according to the invention are 5.4 times superior to trimethoprim.
- the present invention accordingly also relates to chemotherapeutic agents which, in addition to conventional carriers and diluents, contain a compound of the formula I, in particular in combination with a sulfonamide, as active ingredients, and the use of the compounds of the formula I as sulfonamide potentiators.
- chemotherapeutic agents or preparations are produced in a known manner with the usual carriers or diluents and the commonly used pharmaceutical-technical auxiliaries in accordance with the desired type of application.
- the preferred preparations are in a dosage form which is suitable for oral administration.
- Dosage forms of this type are, for example, tablets, film-coated tablets, dragees, capsules, pills, powders, solutions or suspensions.
- the active ingredients are mixed with corn starch and granulated with an aqueous gelatin solution.
- the dry granulate is sieved and mixed with the aggregates. Tablets are pressed from this mixture in the usual way.
- the active ingredients are granulated with aqueous gelatin solution and, after drying, mixed with corn starch, talc and magnesium stearate. Tablets are pressed from this mixture in the usual way.
- the active ingredient is mixed with corn starch and granulated with aqueous gelatin solution.
- the dry granulate is sieved and mixed with the aggregates. Tablets are pressed from this mixture in the usual way.
- the active ingredient is granulated with aqueous gelatin solution and, after drying, is mixed with corn starch, talc and magnesium stearate. Tablets are pressed from this mixture in the usual way. the finely ground active ingredients are suspended in the aqueous tylose mucus. Then all other ingredients are added in succession with stirring. Finally, make up to 100.0 with water.
- the finely ground active ingredient is suspended in the aqueous tylose mucus. Then all other ingredients are added in succession with stirring. Finally, make up to 100.0 with water.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2732029 | 1977-07-15 | ||
DE19772732029 DE2732029A1 (de) | 1977-07-15 | 1977-07-15 | Neue amidino-benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000336A1 true EP0000336A1 (fr) | 1979-01-24 |
EP0000336B1 EP0000336B1 (fr) | 1981-04-15 |
Family
ID=6014014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100184A Expired EP0000336B1 (fr) | 1977-07-15 | 1978-06-19 | N-benzylpyrimidinyl-amidines, procédé pour leur préparation et médicaments les contenant |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0000336B1 (fr) |
JP (1) | JPS5419986A (fr) |
AR (1) | AR227759A1 (fr) |
AT (1) | AT360999B (fr) |
AU (1) | AU520820B2 (fr) |
CA (1) | CA1129410A (fr) |
DE (2) | DE2732029A1 (fr) |
DK (1) | DK143273C (fr) |
FI (1) | FI782221A (fr) |
HU (1) | HU179408B (fr) |
IE (1) | IE47022B1 (fr) |
IL (1) | IL55063A0 (fr) |
IT (1) | IT1096976B (fr) |
NO (1) | NO782455L (fr) |
ZA (1) | ZA784012B (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315931A (en) * | 1977-07-06 | 1982-02-16 | Basf Aktiengesellschaft | N-Pyrimidinyl-imidoacid esters and drugs containing the said compounds |
US4333936A (en) * | 1978-07-03 | 1982-06-08 | Basf Aktiengesellschaft | Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof |
EP0053695A2 (fr) * | 1980-12-04 | 1982-06-16 | BASF Aktiengesellschaft | Esters de l'acide N-pyrimidinylcarbamique, leur procédé de préparation et médicaments les contenant |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5915110U (ja) * | 1982-07-22 | 1984-01-30 | クラリオン株式会社 | 定電圧回路 |
JPH0618012B2 (ja) * | 1983-01-25 | 1994-03-09 | セイコーエプソン株式会社 | 定電圧回路 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4849791A (fr) * | 1971-10-26 | 1973-07-13 |
-
1977
- 1977-07-15 DE DE19772732029 patent/DE2732029A1/de not_active Withdrawn
-
1978
- 1978-06-19 EP EP78100184A patent/EP0000336B1/fr not_active Expired
- 1978-06-19 DE DE7878100184T patent/DE2860614D1/de not_active Expired
- 1978-07-03 IL IL55063A patent/IL55063A0/xx unknown
- 1978-07-05 IE IE1354/78A patent/IE47022B1/en unknown
- 1978-07-05 IT IT25382/78A patent/IT1096976B/it active
- 1978-07-10 AU AU37903/78A patent/AU520820B2/en not_active Expired
- 1978-07-11 FI FI782221A patent/FI782221A/fi not_active Application Discontinuation
- 1978-07-11 AR AR272912A patent/AR227759A1/es active
- 1978-07-13 JP JP8462878A patent/JPS5419986A/ja active Pending
- 1978-07-13 HU HU78BA3676A patent/HU179408B/hu unknown
- 1978-07-14 NO NO782455A patent/NO782455L/no unknown
- 1978-07-14 CA CA307,427A patent/CA1129410A/fr not_active Expired
- 1978-07-14 ZA ZA00784012A patent/ZA784012B/xx unknown
- 1978-07-14 DK DK315878A patent/DK143273C/da not_active IP Right Cessation
- 1978-07-14 AT AT513078A patent/AT360999B/de not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4849791A (fr) * | 1971-10-26 | 1973-07-13 |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 79 (1973), Nr. 19, Seite 362, Spalte 2, P115.615 c & JP-A-48 049 791 (TOKUYAMA KANJI & NISHINO TAKENORI) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315931A (en) * | 1977-07-06 | 1982-02-16 | Basf Aktiengesellschaft | N-Pyrimidinyl-imidoacid esters and drugs containing the said compounds |
US4333936A (en) * | 1978-07-03 | 1982-06-08 | Basf Aktiengesellschaft | Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof |
EP0053695A2 (fr) * | 1980-12-04 | 1982-06-16 | BASF Aktiengesellschaft | Esters de l'acide N-pyrimidinylcarbamique, leur procédé de préparation et médicaments les contenant |
EP0053695A3 (fr) * | 1980-12-04 | 1982-12-15 | BASF Aktiengesellschaft | Esters de l'acide N-pyrimidinylcarbamique, leur procédé de préparation et médicaments les contenant |
Also Published As
Publication number | Publication date |
---|---|
DK315878A (da) | 1979-01-16 |
CA1129410A (fr) | 1982-08-10 |
EP0000336B1 (fr) | 1981-04-15 |
AU520820B2 (en) | 1982-03-04 |
IE47022B1 (en) | 1983-11-30 |
DK143273B (da) | 1981-08-03 |
DK143273C (da) | 1981-11-30 |
FI782221A (fi) | 1979-01-16 |
DE2860614D1 (en) | 1981-05-07 |
AR227759A1 (es) | 1982-12-15 |
AT360999B (de) | 1981-02-10 |
IE781354L (en) | 1979-01-15 |
IT7825382A0 (it) | 1978-07-05 |
DE2732029A1 (de) | 1979-02-01 |
HU179408B (en) | 1982-10-28 |
ATA513078A (de) | 1980-07-15 |
AU3790378A (en) | 1980-01-17 |
IL55063A0 (en) | 1978-09-29 |
JPS5419986A (en) | 1979-02-15 |
ZA784012B (en) | 1979-08-29 |
IT1096976B (it) | 1985-08-26 |
NO782455L (no) | 1979-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH648027A5 (de) | Guanidinothiazolverbindungen, verfahren zu deren herstellung und arzneimittelzubereitungen. | |
CH637385A5 (de) | Verfahren zur herstellung von pyrimidin-derivaten und von deren pharmakologisch vertraeglichen salzen. | |
EP0163260B1 (fr) | Nouvelles pyrrolidones substituées, procédé pour leur préparation et médicaments | |
DE2847792C2 (fr) | ||
CH671225A5 (fr) | ||
EP0000336B1 (fr) | N-benzylpyrimidinyl-amidines, procédé pour leur préparation et médicaments les contenant | |
EP0000334B1 (fr) | 2,4-Diamino-5-benzylpyrimidines, procédé pour leur préparation et médicaments les contenant | |
DE2833986A1 (de) | Immunstimulierende n-substituierte aziridin-2-carbonsaeurederivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese substanzen enthalten | |
DE2815442C2 (fr) | ||
CH634566A5 (de) | Benzylpyrimidine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
EP0000335B1 (fr) | Esters de l'acide N-pyrimidinyl-carboximidique, procédé pour leur préparation et médicaments les contenant. | |
DE1813918C3 (de) | 2-Hydroxymethyl-3-carbonsäureamido--chinoxalin-M-di-N-oxide, ein Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende antibakterielle Mittel | |
EP0097297B1 (fr) | 5-Phénylthio-6-amino-pyrimidinones substituées, leur procédé de préparation et leur usage, de même que les préparations contenant ces composés | |
EP0088323B1 (fr) | Amides d'acides imidazothiadiazolealcanecarboxyliques, produits intermédiaires pour leur fabrication, leur fabrication et leur application en médicaments | |
EP0121490A1 (fr) | 6-Aryl-1,2,4-triazolo[4,3-b]pyridazines substituées, leur préparation et utilisation | |
EP0004904B1 (fr) | Dérivés de 2-amino-3a,4,5,6-tétrahydropérimidine, médicaments les contenant et procédé pour leur préparation | |
DE1695689B2 (de) | 3- (5-nitro-2-thenylidenamino) -oxazolidon-(2)-derivate | |
CH634069A5 (en) | Process for preparing novel 7-substituted 7H-pyrrolo[3,2-f]quinazoline-1,3-diamines | |
DE2439283A1 (de) | Neue pyrimidinderivate und verfahren zu deren herstellung | |
DE1241437B (de) | Verfahren zur Herstellung von Biguanid-guanylhydrazonverbindungen | |
DD202288A5 (de) | Verfahren zur herstellung von phenylpiperazinderivaten | |
CH653335A5 (de) | Verfahren zur herstellung von 9-amino-6,7dihydro-4h-pyrido (1,2-a)pyrimidin-4-on-derivaten. | |
AT273964B (de) | Verfahren zur Herstellung von neuen benzheterocyclischen Verbindungen und ihren Salzen | |
DE2236339A1 (de) | Verfahren zur herstellung von alphacyan-hydrazonen | |
AT255034B (de) | Verfahren zur Herstellung von O, S-Dialkoxycarbonylthiaminen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2860614 Country of ref document: DE Date of ref document: 19810507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19810630 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19820525 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19820630 Year of fee payment: 5 Ref country code: NL Payment date: 19820630 Year of fee payment: 5 Ref country code: DE Payment date: 19820630 Year of fee payment: 5 Ref country code: CH Payment date: 19820630 Year of fee payment: 5 Ref country code: BE Payment date: 19820630 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19820705 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19830429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19830619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19830620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19830630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19840101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19840229 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100184.7 Effective date: 19850610 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |